Theriva Biologics Inc [AMEX: TOVX] traded at a low on 2025-11-20, posting a -6.95 loss after which it closed the day’ session at $0.21.
The results of the trading session contributed to over 3857610 shares changing hands. Over the past one week, the price volatility of Theriva Biologics Inc stands at 13.51% while the volatility over the past one month is 17.57%.
The market cap for TOVX stock reached $7.23 million, with 33.74 million shares outstanding and 32.97 million shares in the current float. Compared to the average trading volume of 14.38M shares, TOVX reached a trading volume of 3857610 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Theriva Biologics Inc [TOVX]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TOVX shares is $7.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TOVX stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Price to Book ratio for the last quarter was 0.33, with the Price to Cash per share for the same quarter was set at 0.22.
How has TOVX stock performed recently?
Theriva Biologics Inc [TOVX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -22.07. With this latest performance, TOVX shares dropped by -26.61% in over the last four-week period, additionally sinking by -53.78% over the last 6 months – not to mention a drop of -87.75% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TOVX stock in for the last two-week period is set at 36.58, with the RSI for the last a single of trading hit 0.0412, and the three-weeks RSI is set at 0.0545 for Theriva Biologics Inc [TOVX]. The present Moving Average for the last 50 days of trading for this stock 0.3683, while it was recorded at 0.2408 for the last single week of trading, and 0.7072 for the last 200 days.
Theriva Biologics Inc (TOVX) Capital Structure & Debt Analysis
According to recent financial data for Theriva Biologics Inc. ( TOVX), the Return on Equity (ROE) stands at -166.96%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -73.83%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Theriva Biologics Inc’s Return on Invested Capital (ROIC) is -296.77%, showcasing its effectiveness in deploying capital for earnings.
Theriva Biologics Inc (TOVX) Efficiency & Liquidity Metrics
Based on Theriva Biologics Inc’s (TOVX) latest financial statements, the Debt-to-Equity Ratio is 0.41%, indicating its reliance on debt financing relative to shareholder equity.
Theriva Biologics Inc (TOVX) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Theriva Biologics Inc. (TOVX) effectively leverages its workforce, generating an average of -$1190454.55 per employee. The company’s liquidity position is robust, with a Current Ratio of 0.90% and a Quick Ratio of 0.90%, indicating strong ability to cover short-term liabilities.
Earnings analysis for Theriva Biologics Inc [TOVX]
With the latest financial reports released by the company, Theriva Biologics Inc posted -11.49/share EPS, while the average EPS was predicted by analysts to be reported at -7.22/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -4.27. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TOVX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Theriva Biologics Inc go to 51.81%.
Insider trade positions for Theriva Biologics Inc [TOVX]
There are presently around $1.31%, or 1.31%% of TOVX stock, in the hands of institutional investors. The top three institutional holders of TOVX stocks are: MSD PARTNERS, L.P. with ownership of 0.6 million shares, which is approximately 3.4898%. VANGUARD GROUP INC, holding 0.19 million shares of the stock with an approximate value of $$45959.0 in TOVX stocks shares; and VANGUARD GROUP INC, currently with $$44703.0 in TOVX stock with ownership which is approximately 1.1033%.
